The drug company Boehringer Ingelheim has issued a recall of its anticoagulant medication Pradaxa (Dabigatran) for what the company says is a manufacturing defect. The defect has to do with the moisture levels that may reach the pills because of a structural problem with the bottles they are encased in, Boehringer says.
The moisture that could reach the pills is believed to reduce the overall quality of the medication. The recall was voluntary and concerns just one lot of the Dabigatran in the 75 mg dose that was distributed in the United States and Puerto Rico. Dabigatran is an FDA-approved treatment for patients who have nonvalvular atrial fibrillation and is used to help prevent strokes and systemic embolisms. Any patients who received lot 201900 of Dabigatran are encouraged to take the drug until they receive a replacement bottle of the drug. Patients can get a replacement by bringing their bottles to their pharmacists to be replaced free of charge. Pharmacists have been given notification of the recall, and will contact those patients who were given the affected lot.
Anticoagulants are a common prescription medication used to treat AF patients. Atrial fibrillation is a condition that is characterized by patients experiencing irregular heartbeats and flutters. The condition can also lead many patients to suffer from strokes. Many different anticoagulants are used to treat AF including Multaq. Multaq is manufactured by Sanofi-Aventis, and has been linked to liver failure and a worsening of the heart condition that has caused the FDA to recommend that doctors avoid prescribing the drug unless all other medications fail.
If you have suffered from liver failure or a worsening of the heart condition after taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.